|
Xtant Medical Holdings Inc (NYSEAMER: XTNT) |
|
Xtant Medical Holdings Inc
XTNT's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Xtant Medical Holdings Inc growth rates, revenue grew
by 14.95 % in the fourth quarter of 2024 from the same quarter a year ago.
Ranking at No. 676
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -2.05 %
Xtant Medical Holdings Inc net loss decreased from $-4 millions, to $-3 millions in fourth quarter of 2024,
• More on XTNT's Growth
|
|
Xtant Medical Holdings Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 276.04 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.7.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.2.
• More on XTNT's Valuation
|
|
|
|
|
Xtant Medical Holdings Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 276.04 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.7.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.2.
Xtant Medical Holdings Inc Price to Book Ratio is at 1.91 lower than Industry Avg. of 1878.65. and higher than S&P 500 Avg. of 0.01
• More on XTNT's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com